Aerovate Therapeutics, Inc. (AVTE) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Waltham, MA, 미국. 현재 CEO는 Timothy P. Noyes.
AVTE 을(를) 보유 IPO 날짜 2021-06-30, 4 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $77.68M.
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
